Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Journal of Gastrointestinal Cancer|April 21, 2022
The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma PatientsMatthew Parsons, Shane Lloyd, Skyler Johnson, et al.
ESMO Open|August 11, 2018
Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapyChristopher Nevala-Plagemann, Samual Francis, Courtney Cavalieri, et al.
Oncoscience|April 22, 2015
N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012Ignacio Garrido-Laguna, Danielle Tometich, Nan Hu, et al.
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.
JAMA Network Open|January 8, 2025
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic AdenocarcinomaCarter Norton, Matthew Steven Shaw, Zachary Rubnitz, et al.
Annals of Surgical Oncology|October 19, 2017
Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched AnalysisAnna Torgeson, Shane Lloyd, Dustin Boothe, et al.
Oncoscience|January 17, 2015
A framework for genomic biomarker actionability and its use in clinical decision makingSmruti J Vidwans, Michelle L Turski, Filip Janku, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatmentIgnacio Garrido-Laguna, Filip Janku, Gerald S Falchook, et al.
Cell Reports|August 7, 2020
Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven CancerAria Vaishnavi, Michael T Scherzer, Conan G Kinsey, et al.
Cancer|August 9, 2011
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer CenterIgnacio Garrido-Laguna, Filip Janku, Christos Vaklavas, et al.
Pageof 11